LONDON September 29th, 2021 – Immunidex Ltd, an innovative AI healthcare start up, has signed an agreement with Curisin Inc., India, with the intention to build an Immune Index diagnostic platform that generates a risk score prediction for a patient’s COVID-19 and overall immune health.
Curisin is a Company based in the US that has acquired a significant healthcare platform in India that contains a network of 40,000 doctors and 30,000 patients. Curisin collects significant medical data on chronic disease and immunology and intends to work with Immunidex in two parts.
Since the outbreak of Coronavirus in December 2019, tools for its diagnosis have relied on virus detection in laboratories, including the finessing of this process for variants of concern. In this time, we have observed the increasing trend for antibody tests for COVID-19, yet the US Food and Drug Administration insists that a patient’s level of COVID-19 immunity or protection should not be evaluated by SARS-CoV-2 antibody tests (especially after the person received a COVID-19 vaccination). Those tests provide no information about how strong antibodies may fight against different coronavirus variants*. Finally, the fact that antibodies are detectable from 6 to 12 months after COVID-19 infection** enhances the need and conviction from Immunidex that we should search for far clearer tools to screen patients and their risk against COVID-19.
Adrian Matysek comments “Immunidex has taken a massive step in the field of biomarkers application for COVID-19 by signing this agreement. We are excited to have Curisin at our side as a valued partner in this important challenge. We want to protect people’s health by utilising our innovative screening tools in a medical setting. This is a big chance for all of us to face the demands of living in a new reality of preventive care—striking against potential disease and illness without unnecessary drugs.”
*Thomson H. Should you measure your antibody levels after a coronavirus vaccine? […]. New Sci. 2021;249(3325):10.
** Wang, Z., Muecksch, F., Schaefer-Babajew, D. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595, 426–431 (2021)
